Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cephalon Australia

Division of Teva Pharmaceutical Industries Ltd.

Latest From Cephalon Australia

Chiplin named chief at Polynoma

Oncology-focused biotech, Polynoma, which is part of Hong Kong-based CK Life Sciences, has appointed Dr John Chiplin CEO. Dr Chiplin has over 25 years of biopharmaceutical experience having most recently served as founding CEO of Arana Therapeutics.

Hong Kong

Cashed-up Scancell aims at 'the UK solution' - proof of concept and acquisition

With the confirmation of second tranche payment of £2.85 million from Arana Therapeutics for an asset it sold in 2006, the UK immunology company, Scancell Holdings is now in a position to push towards its endgame of acquisition by a larger firm in search of a Phase II cancer vaccine asset and cancer vaccine platform.


Deals Shaping the Medical Industry (02/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Inflammation: A Hot Space Gets Complicated

The inflammatory cascade linked to autoimmune disorders like rheumatoid arthritis, psoriasis, systemic lupus erythematosus, Crohn's disease, multiple sclerosis, ankylosing spondylitis, and transplant rejection causes heat. It also sparks biotech dealmaking. Lots of it and at high premiums for even midstage licenses. Even as the biodollars grow, the expansion of therapeutics and maturing of the marketplace could lead to new complexities that predict both opportunity and risk for emerging companies.

See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Peptide Technology Ltd.
  • Peptech Ltd.
  • Arana Therapeutics Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Teva Pharmaceutical Industries Ltd.
  • Senior Management
  • Steffan Nock, PhD, Acting CEO, Pres. US Ops.
    Niall Henderson, CFO & Co. Secretary
    Rob Crombie, PhD, VP, Bus. Dev. - Technology
    Cliff Holloway, PhD, VP, Bus. Dev. - Products
  • Contact Info
  • Cephalon Australia
    Phone: (61) 2 8061 9900
    37 Epping Rd.
    Level 2
    Macquarie Park, 2113